Your browser doesn't support javascript.
loading
Brain volume change in first-episode psychosis: an effect of antipsychotic medication independent of BMI change.
Jørgensen, K N; Nesvåg, R; Nerland, S; Mørch-Johnsen, L; Westlye, L T; Lange, E H; Haukvik, U K; Hartberg, C B; Melle, I; Andreassen, O A; Agartz, I.
Afiliação
  • Jørgensen KN; Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway.
  • Nesvåg R; NORMENT and K.G. Jebsen Center for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Nerland S; Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway.
  • Mørch-Johnsen L; Norwegian Institute of Public Health, Oslo, Norway.
  • Westlye LT; Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway.
  • Lange EH; Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway.
  • Haukvik UK; NORMENT and K.G. Jebsen Center for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Hartberg CB; NORMENT and K.G. Jebsen Center for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Melle I; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
  • Andreassen OA; Department of Psychology, University of Oslo, Oslo, Norway.
  • Agartz I; Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway.
Acta Psychiatr Scand ; 135(2): 117-126, 2017 Feb.
Article em En | MEDLINE | ID: mdl-27925164
ABSTRACT

OBJECTIVE:

The effect of antipsychotic medication on brain structure remains unclear. Given the prevalence of weight gain as a side-effect, body mass index (BMI) change could be a confounder.

METHOD:

Patients with first-episode psychosis (n = 78) and healthy controls (n = 119) underwent two 1.5T MRI scans with a 1-year follow-up interval. siena (fsl 5.0) was used to measure whole-brain volume change. Weight and height were measured at both time points. Antipsychotic medication use at baseline and follow-up was converted into chlorpromazine equivalent dose and averaged.

RESULTS:

Patients did not show significantly larger brain volume loss compared with healthy controls. In the whole sample (n = 197), BMI change was negatively associated with brain volume change (ß = -0.19, P = 0.008); there was no interaction effect of group. Among patients, higher antipsychotic medication dosage was associated with greater brain volume loss (ß = -0.45, P < 0.001). This association was not affected by adjusting for BMI change.

CONCLUSION:

Weight gain was related to brain volume reductions to a similar degree among patients and controls. Antipsychotic dosage-related reductions of brain volume were not confounded by BMI change. Generalizability to contexts involving severe weight gain needs to be established. Furthermore, disentangling effects of medication from illness severity remains a challenge.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos / Antipsicóticos / Encéfalo / Clorpromazina Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos / Antipsicóticos / Encéfalo / Clorpromazina Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article